Definium Therapeutics (DFTX) Current Assets (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Current Assets data on file, last reported at $380.6 million in Q1 2026.

• On a quarterly basis, Current Assets rose 71.66% year-over-year to $380.6 million in Q1 2026; TTM through Mar 2026 was $380.6 million, a 71.66% increase from a year earlier, with the FY2025 full-year figure at $419.3 million, up 48.9% from the prior year.
• Current Assets for Q1 2026 stood at $380.6 million, down from $419.3 million in the prior quarter.
• Over the last five years, Current Assets for DFTX reached as high as $419.3 million in Q4 2025 and fell as low as $103.9 million in Q4 2023.
• Historically, Current Assets has averaged $207.2 million across 5 years, with a median of $189.1 million in 2025.
• Across the five-year window, Current Assets declined 28.88% in 2023 and jumped 171.12% in 2024, its largest moves.
• Year by year, Current Assets stood at $146.1 million in 2022, then retreated by 28.88% to $103.9 million in 2023, then soared by 171.12% to $281.6 million in 2024, then jumped by 48.9% to $419.3 million in 2025, then decreased by 9.24% to $380.6 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $380.6 million in Q1 2026, $419.3 million in Q4 2025, and $215.8 million in Q3 2025.